Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) EBITDA Margin (2018 - 2025)

Cue Biopharma (CUE) has disclosed EBITDA Margin for 8 consecutive years, with 242.62% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 84516.0% to 242.62% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 34.19% through Dec 2025, up 40378.0% year-over-year, with the annual reading at 19.96% for FY2025, 41801.0% up from the prior year.
  • EBITDA Margin hit 242.62% in Q4 2025 for Cue Biopharma, up from 346.53% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 242.62% in Q4 2025 to a low of 50800.0% in Q2 2022.
  • Historically, EBITDA Margin has averaged 4721.07% across 5 years, with a median of 660.82% in 2024.
  • Biggest five-year swings in EBITDA Margin: plummeted -5042472bps in 2022 and later soared 4984841bps in 2023.
  • Year by year, EBITDA Margin stood at 101.57% in 2021, then tumbled by -9416bps to 9666.23% in 2022, then soared by 92bps to 737.73% in 2023, then increased by 18bps to 602.54% in 2024, then surged by 140bps to 242.62% in 2025.
  • Business Quant data shows EBITDA Margin for CUE at 242.62% in Q4 2025, 346.53% in Q3 2025, and 287.14% in Q2 2025.